Abstract 72P
Background
The PACIFIC trial established consolidation therapy with durvalumab as the standard of care for patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) without progression after chemoradiotherapy (CRT), however, additional studies are still needed to further explore the optimal therapeutic strategies. Here, we reported the preliminary results of the phase 2 study of camrelizumab (an anti-PD-1 antibody) plus apatinib (an anti-angiogenic inhibitor targeting VEGFR2) as consolidation therapy after CRT in unresectable stage III NSCLC.
Methods
This was a multi-center, single-arm, phase 2 study done at seven sites in China. Adult pts with pathologically confirmed unresectable stage III NSCLC, an ECOG PS of 0 or 1, and no disease progression following platinum-based concurrent or sequential CRT received camrelizumab (200 mg, i.v., q3w) and apatinib (250 mg, orally, qd) until disease progression, unacceptable toxicity or for up to 12 months. The primary endpoint was progression-free survival (PFS).
Results
Between March 17, 2021 to July 17, 2023, 42 pts were enrolled. The median age was 61 years (range 26-78), with 39 pts (92.9%) being male and 31 (73.8%) having squamous NSCLC. According to RECIST 1.1, three (7.1%) of the 42 pts had a complete response and eight (19.0%) had a partial response, with the confirmed objective response rate of 26.2% (95% CI 13.9-42.0). Twenty-three pts (54.8%) had stable disease, with the disease control rate of 81.0 % (95% CI 65.9-91.4). As of August 28, 2023, the median follow-up was 11.4 months (95% CI 5.8-15.6). The median PFS was not reached (NR; 95% CI 11.4-NR), with the 6- and 12-month PFS rates of 88.8% (95% CI 72.8-95.7) and 68.6% (95% CI 47.4-82.7), respectively. The median overall survival was immature, with six deaths at data cutoff. Treatment-related adverse events (TRAEs) of grade 3-4 occurred in 18 pts (42.8%), with the most common being hypertension (21.4%), AST increased (7.1%) and hand-foot syndrome (4.8%). No grade 5 TRAEs occurred.
Conclusions
Camrelizumab plus apatinib as consolidation therapy showed preliminary activity in unresectable stage III NSCLC pts without disease progression after CRT, with no new safety signals.
Clinical trial identification
NCT04749394; February 11, 2021.
Legal entity responsible for the study
Cancer Hospital Chinese Academy of Medical Sciences.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - A prospective, single-arm, phase II study to evaluate the efficacy and safety of Tislelizumab plus chemotherapy in resectable NSCLC
Presenter: Daqiang Sun
Session: Poster Display
80P - Efficacy and Safety of Tislelizumab Combined with Anlotinib and 2-cycles Chemotherapy as First-line Treatment for Advanced NSCLC(TISAL-FE-01)
Presenter: jun Tang
Session: Poster Display
81P - Real-World Experience with Docetaxel Regimens in Metastatic Non-Squamous (mNSq) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated with Platinum-Based Chemotherapy (PCT) and an Immune Checkpoint Inhibitor (ICI) in the United States (US)
Presenter: Marisa Bittoni
Session: Poster Display
82P - The Role of Circadian Rhythms in NSCLC Immunotherapy Efficacy: A Focus on First Dose Timing
Presenter: Martin Igor Gomez-Randulfe Rodriguez
Session: Poster Display
84P - Adebrelimab plus chemotherapy (chemo) as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC): 3-year update of the phase 3 CAPSTONE-1 study
Presenter: Ying Cheng
Session: Poster Display
85P - Phase II trial of tislelizumab plus sitravatinib as maintenance therapy in extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Yun Fan
Session: Poster Display
86P - Durvalumab plus Olaparib as maintenance therapy in extensive-stage small-cell lung cancer (TRIDENT): updated efficacy and safety analysis
Presenter: Yan Huang
Session: Poster Display
88P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: MARA PERSANO
Session: Poster Display